

**Prof. Özlem Türeci, M.D.**  
**Chief Medical Officer**

<b>Year of Birth</b>	1967
<b>Nationality</b>	German
<b>Management Board Member of BioNTech SE since</b>	2018
<b>End of current appointment</b>	2025
<b>Memberships in statutory Supervisory Boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises</b>	
CIMT e.V. (The Association for Cancer Immunotherapy) Mainz, Germany (non-listed company)	Chair of the Executive Board

Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience. Türeci has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf vaccine candidates and other types of immunotherapies which are currently in clinical development. Türeci leads the clinical development of BioNTech’s “Project Lightspeed,” the company’s successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year.

Türeci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. She is also a professor for Personalized Immunotherapy at the University Medical Center Mainz and the Helmholtz Institute for Translational Oncology Mainz (HI-TRON) and currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recipient of the German Sustainability Award, among other notable recognitions. Türeci is married to Prof. Ugur Sahin.